Mgr. Šárka Pavlová, Ph.D.

2017

• KOTASKOVA, J; PAVLOVA, S; PLEVOVA, K; MALCIKOVA, J; STEHLIKOVA, O; POPPOVA, L; KOCKOVA, H; DOUBEK, M; BRYJA, V; POSPISILOVA, S, 2017:TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102 , p. 414 - 414.
• PLEVOVA, K; MALCIKOVA, J; PAVLOVA, S; KOTASKOVA, J; POPPOVA, L; SMARDOVA, J; DIVISKOVA, E; DURECHOVA, K; OLTOVA, A; BRYCHTOVA, Y; PANOVSKA, A; DOUBEK, M; POSPISILOVA, S, 2017:BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102 , p. 65 - 66.

2016

• JANOVSKA, P; POPPOVA, L; PLEVOVA, K; PLESINGEROVA, H; BEHAL, M; KAUCKA, M; OVESNA, P; HLOZKOVA, M; BORSKY, M; STEHLIKOVA, O; BRYCHTOVA, Y; DOUBEK, M; MACHALOVA, M; BASKAR, S; KOZUBIK, A; POSPISILOVA, S; PAVLOVA, S; BRYJA, V, 2016:Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. CLINICAL CANCER RESEARCH 22 (2), p. 459 - 469.
• KOTASKOVA, J; PAVLOVA, S; GREIF, I; STEHLIKOVA, O; PLEVOVA, K; JANOVSKA, P; BRYCHTOVA, Y; DOUBEK, M; POSPISILOVA, S; BRYJA, V, 2016:ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. BRITISH JOURNAL OF HAEMATOLOGY 175 (2), p. 339 - 342.
• KUBESOVA, B; PAVLOVA, S; MALCIKOVA, J; KABATHOVA, J; RADOVA, L; TOM, N; TICHY, B; PLEVOVA, K; KANTOROVA, B; FIEDOROVA, K; KISSOVA, J; GISSLINGER, B; GISSLINGER, H; MAYER, J; KRALOVICS, R; POSPISILOVA, S; DOUBEK, M, 2016:Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128 (22)
• POPPOVA, L; JANOVSKA, P; PLEVOVA, K; RADOVA, L; PLESINGEROVA, H; BORSKY, M; KOTASKOVA, J; KANTOROVA, B; HLOZKOVA, M; FIGULOVA, J; BRYCHTOVA, Y; DOUBEK, M; KOZUBIK, A; POSPISILOVA, S; PAVLOVA, S; BRYJA, V, 2016:DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND, IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL IN MUTATED IGHV SUBSET. HAEMATOLOGICA 101 , p. 423 - 424.
• POPPOVA, L; JANOVSKA, P; PLEVOVA, K; RADOVA, L; PLESINGEROVA, H; BORSKY, M; KOTASKOVA, J; KANTOROVA, B; HLOZKOVA, M; FIGULOVA, J; BRYCHTOVA, Y; MACHALOVA, M; URIK, M; DOUBEK, M; KOZUBIK, A; POSPISILOVA, S; PAVLOVA, S; BRYJA, V, 2016:Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. BRITISH JOURNAL OF HAEMATOLOGY 175 (5), p. 851 - 859.

2015

• KOTASKOVA, J; MALCIKOVA, J; DIVISKOVA, E; PAVLOVA, S; MEJSTRIKOVA, S; VRANOVA, V; PLEVOVA, K; PLESINGEROVA, H; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2015:13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100 , p. 417 - 418.
• MALCIKOVA, J; STANO-KOZUBIK, K; TICHY, B; KANTOROVA, B; PAVLOVA, S; TOM, N; RADOVA, L; SMARDOVA, J; PARDY, F; DOUBEK, M; BRYCHTOVA, Y; MRAZ, M; PLEVOVA, K; DIVISKOVA, E; OLTOVA, A; MAYER, J; POSPISILOVA, S; TRBUSEK, M, 2015:Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. LEUKEMIA 29 (4), p. 877 - 885.
• PLESINGEROVA, H; JANOVSKA, P; POPPOVA, L; SHAIK, A; JURCICKOVA, Z; LIBRA, A; PLEVOVA, K; MACHAC, J; SLAPAK, I; PAVLOVA, S; OVESNA, P; KOTASKOVA, J; DOUBEK, M; POSPISILOVA, S; BRYJA, V, 2015:UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH INFERIOR PROGNOSIS. HAEMATOLOGICA 100 , p. 50 - 50.
• TOM, N; MALCIKOVA, J; RADOVA, L; KANTOROVA, B; PARDY, F; PAVLOVA, S; PAL, K; MRAZ, M; TICHY, B; DOUBEK, M; BRYCHTOVA, Y; PLEVOVA, K; MAYER, J; TRBUSEK, M; POSPISILOVA, S, 2015:MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100 , p. 224 - 225.